

- Acute pharyngeal cervicobrachial neuropathy, 2696t
- Acute promyelocytic leukemia (APL)
chemotherapy-associated, 103e-13
chromosome abnormalities in, 102e-7, 431t, 679
peripheral blood smear in, 81e-9f
treatment of, 102e-5t, 102e-7, 103e-16, 686-687
- Acute quadriplegic neuropathy, 462e-20
- Acute radiation syndrome, 263e-2-4, 263e-4f
- Acute renal failure. *See* Acute kidney injury (AKI)
- Acute respiratory distress syndrome (ARDS), **1736**
clinical course of, 1736-1738, 1736f, 1737f, 1738f
diagnosis of, 1736t
chest radiography, 308e-10f, 1737, 1737f
CT, 308e-10f, 1737, 1738f
disorders associated with, 1736, 1736t
etiology of, 1736
functional recovery after, 1740
HSV infection and, 1180
incidence of, 1736
pathophysiology of, 1736-1738, 1737f
pressure-volume relationships in, 1732f
prognosis of, 1739-1740
in sepsis/septic shock, 1755
in shock, 1746
treatment of, 1738-1739, 1739f, 1739t. *See also* Mechanical ventilation
- Acute rheumatic fever. *See* Rheumatic fever
- Acute tubular necrosis (ATN). *See* Acute kidney injury (AKI)
- Acyclovir
action of, 214e-4, 215e-6, 896-897
adverse effects of
gastrointestinal, 897
hematologic, 897
musculoskeletal, 2218t
neurologic, 215e-7, 897, 2547t
renal, 215e-7, 1181, 1804
for Bell's palsy, 2648
global considerations in, 1183
for herpes zoster, 215e-3-4t, 215e-7, 832t, 1186, 2657
for HSV infections
encephalitis, 215e-2t, 1179, 1181, 1182t
esophagitis, 1182t, 1910
genital, 215e-2t, 215e-7, 832t, 1182t
mucocutaneous, 215e-7, 233, 1182t
in neonates, 1180, 1182t
ocular, 200
pharyngitis, 233
as prophylaxis in HIV infection, 1253t
as prophylaxis in transplant recipient, 139e-4t, 215e-6, 921, 925t, 927
for oral hairy leukoplakia, 1190
pharmacology of, 215e-7
resistance to, 215e-7, 897, 1182-1183
for varicella prevention, 917
for varicella treatment, 215e-2t, 215e-7, 1185-1186
for viral encephalitis, 896-897
for viral meningitis, 893
for viral myelitis, 2657
for VZV prophylaxis in HIV infection, 1252t
for VZV prophylaxis in transplant recipient, 139e-4
- AD. *See* Alzheimer's disease (AD)
- Adalimumab
adverse effects of, 348t, 422, 2146t, 2173
for ankylosing spondylitis, 2172-2173
for autoimmune and inflammatory diseases, 372e-30
for IBD, 1961
monitoring during treatment with, 2146t
for psoriasis/psoriatic arthritis, 348t, 2177
for rheumatoid arthritis, 2145, 2146t
for sarcoidosis, 2212
- Adamantinoma, 119e-3
- ADAMTS13, 729, 1863, 2754t
- ADAMTS13 metalloproteinase, 1848
- Adaptive immune system, 372e-2, **372e-16**. *See also* Immune response/immune system
cells triggering, 372e-7t
definition of, 372e-1
immunoglobulins in. *See* Immunoglobulin(s)
innate immune system and, 372e-2
intercellular interactions of, 372e-9f
primary immunodeficiencies of
B lymphocyte deficiencies. *See* B cell(s), deficiencies of
T lymphocyte deficiencies. *See* T cell(s), deficiencies of
PRRs in modulation of, 372e-6t
response to microbes, 372e-23, 372e-26
T cells in. *See* T cell(s)
- Adaptive senescence, 94e-3
- Adaptive servoventilation, 1727
- ADCC (antibody-dependent cell-mediated cytotoxicity), 372e-1, 372e-6, 1244
- Addison's disease. *See also* Adrenal insufficiency
anemia in, 630
APS-1 and, 2345, 2346t
APS-2 and, 2346, 2346t, 2347t
autoantibodies in, 372e-24t, 2346
clinical features of, 2324, 2326f
diarrhea in, 268
genetic considerations in, 2346
hyperkalemia in, 310
hypoglycemia in, 2433
oral manifestations of, 240t
skin manifestations of, 359, 360
thymic tumors in, 2348
- Adefovir
action of, 215e-9
adverse effects of, 215e-9, 2035
for chronic HBV infection, 215e-4t, 215e-9, 2035, 2038f, 2074
for HBV prophylaxis in transplant recipient, 927
resistance to, 2040t
- A-delta (A δ) fibers, 87, 88
- ADEM (acute disseminated encephalomyelitis), 441e-26f, **2673**
- Adenine, 426
- Adenine nucleotide translator (ANT), 372e-24t
- Adenine phosphoribosyltransferase (APRT)
deficiency, 431e-3t, 431e-5-6
- Adeno-associated virus (AAV), 91e-1t, 91e-3, 214e-4, 214e-9
- Adenocarcinoma
bladder, 575. *See also* Bladder cancer
cervix, 595. *See also* Cervical cancer
colon. *See* Colorectal cancer
endometrial. *See* Endometrial cancer
esophagus, 532-533, 533t. *See also* Esophageal cancer
gastric. *See* Gastric adenocarcinoma
lung, 507, 507f. *See also* Lung cancer
small intestinal, 537
of unknown primary, 120e-3, 120e-3f
- Adenocarcinoma in situ, 515-516
- Adenoidectomy, 230
- Adenoma
ACTH-producing. *See* Cushing's syndrome
aldosterone-producing adrenal, **2318**. *See also* Mineralocorticoid excess
clinical features of, 462e-19
diagnosis of, 1619
etiology of, 2318-2319, 2318t
incidence of, 306, 2321t
hepatic, 553-554
parathyroid, 2470. *See also* Hyperparathyroidism
pituitary. *See* Pituitary tumors (adenomas)
polypoid, 536
small intestinal, 536
thyroid, 2303-2304
- Adenoma sebaceum, 359, 364
- Adenomyomatosis, 2083
- Adenosine
adverse effects of, 1467t, 1471t, 1480t, 1484
for arrhythmias, 1479t
dosage of, 1479t
pharmacology of, 1479t
for preexcited tachycardias, 1482
for supraventricular tachycardia, 35, 47, 1483-1484
as vasoconstrictor, 332e-2
for ventricular tachycardia, 1494
- Adenosine deaminase, 288
- Adenosine deaminase deficiency, 91e-2, 375e-1, 431e-3t, 2108
- Adenosine kinase deficiency, 434e-2t
- 5' Adenosine monophosphate-activated protein kinase (AMPK), 94e-5, 102e-13
- Adenosine receptors, 276, 742
- S-Adenosylhomocysteine hydrolase deficiency, 434e-2
- Adenovirus(es)
adherence of, 145e-2t
characteristics of, 1208
enteric, 1286f, 1286t, 1289
fidelity of replication in, 214e-5
gene expression and regulation in, 214e-4
for gene therapy delivery, 91e-1t, 214e-4, 214e-9
host defense inhibition by, 214e-8
laboratory identification of, 214e-9
structure of, 214e-2t, 214e-3f
- Adenovirus infections, **1208**
clinical features of, 1208
conjunctivitis, 199, 1208
diarrhea, 266, 1208, 1289
rash, 362, 362t
upper respiratory, 226, 231, 234, 1202t
diagnosis of, 1208
epidemiology of, 1208
in immunocompromised patient, 1208
prevention of, 1209
in transplant recipient, 920t, 925, 1208
treatment of, 1208
- Adenovirus vaccine, 1209
- Adenylate kinase (AK) deficiency, 654t
- Adenylosuccinate lyase deficiency, 431e-3t, 431e-6
- Adequate intake, 95e-1, 95e-3
- ADH (antidiuretic hormone). *See* Arginine vasopressin (AVP)
- Adhesins, 145e-1
bacterial, 145e-2-3, 145e-2f, 145e-2t, 1043
fungal, 145e-2t, 145e-3
protozoa, 145e-2t, 145e-3
viral, 145e-1-2, 145e-2t
- Adhesive arachnoiditis, lumbar, 117
- Adhesive capsulitis, 2249
- ADHH (autosomal dominant hypocalcemic hypercalciuria), 2483
- Adie's syndrome, 196
- Adipocytes, 415e-2, 415e-3f, 2405
- Adiponectin, 415e-2, 2452
- Adipose stem cells, 453t
- Adipose tissue, 415e-2
- Adipostat, 415e-5
- Adipsin, 415e-2
- ADLs (activities of daily living), 72t, 78t
- Adnexal mass/tumor, 338, 364, 364t, 593, 595
- ADNFLE (autosomal dominant nocturnal frontal lobe epilepsy), 2545t
- Adolescence
ankylosing spondylitis in, 2170
iron requirements in, 626
seizures in, 2546-2547, 2546t
smoking in, 475
sudden cardiac death in, 1767
- Ado-trastuzumab emtansine, 102e-4, 102e-5t, 103e-22
- ADPEAF (autosomal dominant partial epilepsy with auditory features), 2545t
- ADPKD (autosomal dominant polycystic kidney disease). *See* Polycystic kidney disease, autosomal dominant
- ADP receptor antagonists, 747-748. *See also* Clopidogrel; Prasugrel; Ticagrelor
- Adrenalectomy
for adenoma, 1619
for breast cancer, 103e-3, 530t
for Cushing's syndrome, 2273, 2318